What impact will the incoming Trump administration have on the 2017 health care and life sciences regulatory outlook? In this two-part podcast, The New HHS: Tom Price and Value-Based Health Care and The New FDA: Product Development, Pricing and Beyond, Washington, D.C.-based partners Tom Bulleit (health care) and Al Cacozza (life sciences) offer their perspectives on what might lie ahead regarding:
- Rep. Tom Price's nomination to head HHS
- Value-based health care
- Developments at the FDA
- Drug pricing
To learn more about potential regulatory and enforcement developments emanating from Washington, visit Capital Insights.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.